Abzena Plc Has Signed Telix For Diagnostic And Therapeutic Use

Abzena and Telix Sign Licence Agreement for Abzena’s Prostate-Specific Membrane Antigen Antibodies.Under the terms of the Agreement, Abzena has granted Telix an exclusive worldwide, royalty bearing, sub-licensable licence to its prostate-specific membrane antigen (‘PSMA’) antibodies in the field of radio-immunoconjugation.

Details:
www.businesswire.com/news/home/20170717006332/en/Abzena-Telix-Sign-Licence-Agreement-Abzena%E2%80%99s-Prostate-Specific